Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- SWIPEIndependent statistical analysis of Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SWITCHIndependent statistical analysis of Sleep Without Insomnia or The Use of Chronic Hypnotics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03687086).
- SWITCH 2Independent statistical analysis of A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes: primary endpoint results, effect estimate…
- SWITCH PROIndependent statistical analysis of A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study:…
- Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant: Complete Statistical AnalysisIndependent statistical analysis of Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04530630).
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018): Complete Statistical AnalysisIndependent statistical analysis of Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- SWITCHEDIndependent statistical analysis of Switching Individuals in Treatment for Opioid Use Disorder Who Smoke Cigarettes to the SREC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA): Complete Statistical AnalysisIndependent statistical analysis of Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00796705).
- Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years: Complete Statistical AnalysisIndependent statistical analysis of Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years: primary endpoint…
- SXC-2023 Cocaine Interaction Study: Complete Statistical AnalysisIndependent statistical analysis of SXC-2023 Cocaine Interaction Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06343532).
- SYLVIIndependent statistical analysis of Synthetic vs Natural Estrogen in Combined Oral Contraception: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02352090).
- Sym004 in Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Sym004 in Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01117428).
- Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK): Complete Statistical AnalysisIndependent statistical analysis of Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05034328).
- SYMPATICOIndependent statistical analysis of Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SymphonyIndependent statistical analysis of A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder: primary endpoint results, effect…
- SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- SYMPHONYextIndependent statistical analysis of Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Symplicity AFIndependent statistical analysis of Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Symptom Screening Linked to Care Pathways: Complete Statistical AnalysisIndependent statistical analysis of Symptom Screening Linked to Care Pathways: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04614662).
- Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole: Complete Statistical AnalysisIndependent statistical analysis of Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER): Complete Statistical AnalysisIndependent statistical analysis of Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00831233).
- Symptoms-StepsIndependent statistical analysis of In Person and mHealth Coping Skills Training for Symptom Management and Steps in Stem Cell Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Synagis RussiaIndependent statistical analysis of A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and…
- Synergizing Home Health Rehabilitation Therapy: Complete Statistical AnalysisIndependent statistical analysis of Synergizing Home Health Rehabilitation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05411393).
- SynergyIndependent statistical analysis of ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04835441).
- SYNERGYIndependent statistical analysis of Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex: primary endpoint results, effect…
- SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory Biomarkers: Complete Statistical AnalysisIndependent statistical analysis of SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory Biomarkers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01733732).
- Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma: Complete Statistical AnalysisIndependent statistical analysis of Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis: Complete Statistical AnalysisIndependent statistical analysis of Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00361283).
- Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF: Complete Statistical AnalysisIndependent statistical analysis of Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02118831).
- T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020: Complete Statistical AnalysisIndependent statistical analysis of T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01911065).
- T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents: Complete Statistical AnalysisIndependent statistical analysis of T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010: Complete Statistical AnalysisIndependent statistical analysis of T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- T-cell Depleted Alternative Donor Transplantation: Complete Statistical AnalysisIndependent statistical analysis of T-cell Depleted Alternative Donor Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00968864).
- T-Cell Depleted Double UCB for Refractory AML: Complete Statistical AnalysisIndependent statistical analysis of T-Cell Depleted Double UCB for Refractory AML: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01464359).
- T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases: Complete Statistical AnalysisIndependent statistical analysis of T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases: primary endpoint results, effect estimate with confidence interval,…
- T-DEFIndependent statistical analysis of Defibrillation Testing During Implantable Cardioverter Defibrillator (ICD) Replacement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04206371).
- T-DM1Independent statistical analysis of T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03530696).
- T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery: Complete Statistical AnalysisIndependent statistical analysis of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery: primary endpoint results, effect estimate with confidence interval, sample-size…
- T-GENVIH-003 LTFU (Long Term Follow Up) Study: Complete Statistical AnalysisIndependent statistical analysis of T-GENVIH-003 LTFU (Long Term Follow Up) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06034652).
- T-jet®Independent statistical analysis of Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- T-PASSIndependent statistical analysis of Trimodal Prehabilitation for Aneurysm Surgery Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02292927).
- T-RECSIndependent statistical analysis of Treating Respiratory Emergencies in Children Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06074185).
- T1DoingWellIndependent statistical analysis of Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- T1GERIndependent statistical analysis of A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00939653).
- T2BIndependent statistical analysis of Text2Breathe: Enhance Parent Communication to Reduce Pediatric Asthma Disparities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03032159).
- T2D_MTUIndependent statistical analysis of Impact of Muscle and Tendon Dysfunction in People With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- t2pIndependent statistical analysis of txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…